The Inovio Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $5.81 and its highest was $22.93 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $1.76B.
What is Inovio Pharmaceuticals’s price target?
The average price target for Inovio Pharmaceuticals is $9.60. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $20.00 ,the lowest forecast is $6.00. The average price target represents 14.29% Increase from the current price of $8.4.
What do analysts say about Inovio Pharmaceuticals?
Inovio Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Aug 09, 2021 which is in 7 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on May 10, 2021. The company reported -$0.269 earnings per share for the quarter, missing the consensus estimate of -$0.186 by -$0.083.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 209,400,000 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.269 in its last earnings report, missing expectations of -$0.186. Following the earnings report the stock price went down -5.255%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Among the largest hedge funds holding Inovio Pharmaceuticals’s share is Coatue Management, LLC. It holds Inovio Pharmaceuticals’s shares valued at 29M.